ALN VSP

Drug Profile

ALN VSP

Alternative Names: ALN-VSP; ALN-VSP01; ALN-VSP02; ASC-06

Latest Information Update: 07 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action Angiogenesis inhibitors; KIF11 protein inhibitors; RNA interference; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Liver cancer; Liver metastases

Most Recent Events

  • 12 Nov 2012 Alnylam Pharmaceuticals and Tekmira Pharmaceuticals Corporation sign a new licensing agreement regarding RNAi-based therapies, superseding all previous agreements, and resolve all litigation
  • 13 Jul 2012 ALN VSP licensed to Ascletis Pharmaceuticals in China, Hong Kong, Macau and Taiwan
  • 04 Jun 2012 Additional safety and efficacy data from an extension protocol of a phase I trial in Solid tumours with liver involvement presented at the 48th Annual Meeting of the Americal Society of Clinical Oncology (ASCO-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top